(redirected from Blast crisis)
Also found in: Dictionary, Thesaurus, Medical.
Related to Blast crisis: AML


Pathol a sudden change, for better or worse, in the course of a disease
Collins Discovery Encyclopedia, 1st edition © HarperCollins Publishers 2005
The following article is from The Great Soviet Encyclopedia (1979). It might be outdated or ideologically biased.



a sharp turning point in the course of a disease that is accompanied by a drop in elevated body temperature and improvement in the patient’s condition.

A crisis usually occurs in acute-onset diseases with a rapid rise in temperature (croupous inflammation of the lungs, malaria, relapsing fever, and so forth). A crisis is associated with profuse sweating, marked weakness, and sometimes a temporary slowing of cardiac activity. A crisis is the opposite of a gradual subsidence of a pathological process and lowering in temperature called lysis. A crisis is to be distinguished from a pseudocrisis, in which there is only a temporary lowering of temperature and improvement in the patient’s condition. A critical drop in temperature may also occur as a result of removal of the suppurative focus from the patient’s body or administration of powerful antimicrobial agents.

The Great Soviet Encyclopedia, 3rd Edition (1970-1979). © 2010 The Gale Group, Inc. All rights reserved.


The turning point in the course of a disease.
The psychological events associated with a specific stage of life, as an identity crisis or developmental crisis.
McGraw-Hill Dictionary of Scientific & Technical Terms, 6E, Copyright © 2003 by The McGraw-Hill Companies, Inc.
References in periodicals archive ?
CML blast crisis of T-cell lineage can be difficult to differentiate from de novo BCR-ABL1-positive T-cell Acute Lymphoblastic Leukemia (T-ALL) and BCR-ABL1-positive bilineage leukemia [6, 7].
Silver, "Management of chronic myeloid leukemia in blast crisis," Annals of Hematology, vol.
Further targeted investigations led to the diagnosis of CML in extramedullary blast crisis. It is important for physicians to recognize Horner's syndrome, understand its anatomical pathways and associated collateral clinical features for accurate localization, and avoid delay in diagnosis, which can have important neurological prognostic consequences.
Fruehauf and colleagues (2007) discussed the combination of mitoxanthrone and etoposide to treat a blast crisis. Cytarabine-containing regimens are often used as well.To administer these medications, it is important for the nurse to be aware of the side effects of each medication, such as cardiac toxicity, neurological alterations, and pancytopenia.
Total 83 patients with CML were divided in to chronic phase (CP) 62 (74.6%), 17 (20.4%) in the accelerated phase (AP) and 3 (5.0%) in blast crisis (BC).
CEC (%) VEGF Min Max Min Max Healthy subjects 0.030 0.760 CEC 0.0000 0.0530 EPC 0.0000 0.0265 mCEC 0.0000 0.0330 aCEC 0.0000 0.0133 Blast crisis 0.010 2.110 CEC 0.0011 18.9503 EPC 0.0000 3.7587 mCEC 0.0011 18.7066 aCEC 0.0000 0.0329 Chronic phase 0.060 1.150 CEC 0.0000 0.1557 EPC 0.0000 0.0344 mCEC 0.0000 0.1213 aCEC 0.0000 0.0251 Accelerated phase 0.020 3.220 CEC 0.0000 0.0604 EPC 0.0000 0.0586 mCEC 0.0000 0.0430 aCEC 0.0000 0.0116 CEC: circulating endothelial cells; VEGF: vascular endothelial growth factor; EPC: endothelial precursor cells; mCEC: mature circulating endothelial cells; aCEC: activated circulating endothelial cells; min: minimum; max: maximum.
Acute panmyelosis with myelofibrosis usually presents with pancytopenia with extensive fibrosis and increased blasts of erythroid, myeloid, and megakaryocytic lineages seen on bone marrow biopsy; there is no specific cytogenetic abnormality associated with this entity.1 CML in blast crisis is usually associated with a history of a chronic phase with basophilia and splenomegaly, as well as the BCR-ABL fusion gene.
[beta]-arr2 inhibition prevented the establishment as well as development of the blast crisis phase of CML in mice [67].
Dasatinib has also been approved for patients in blast crisis. Nilotinib and dasatinib also show better molecular responses than imatinib in newly diagnosed patients, but this indication has not been approved in South Africa.
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
Monitoring minimal residual disease and controlling drug resistance in chronic myeloid ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia.
"These findings indicate that the loss of miR-328 is probably essential for progression from the chronic phase of the disease to the blast crisis stage," said principal investigator Danilo Perrotti, associate professor of molecular virology, immunology and medical genetics and a member of the Ohio State University Comprehensive Cancer Center-Arthur G.